Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics is expected to benefit from increased CAR-T utilization in the UK, which is projected to enhance its revenue growth significantly in 2026, with estimates reaching approximately $167 million, a year-over-year increase of about 220%. The company’s revenue guidance for Aucatzyl demonstrates promising prospects as well, with forecasts suggesting a 60-80% year-over-year increase, culminating in $120-135 million, supported by an expanding network. As sales accelerate, better margins are anticipated through operational scale, which could positively impact the company's financial performance going forward.

Autolus Therapeutics PLC has experienced a significant decline in share value, with a drop of approximately 48% since July 2025, contrasting sharply with the broader market's performance. The company's revenue growth has stagnated, particularly due to flat sales from its initial launch of Aucatzyl in 1Q25, exacerbated by manufacturing constraints and enrollment gaps that have hindered product availability. Furthermore, the outlook is clouded by numerous risks, including the potential for clinical efficacy below expectations, safety concerns with ongoing programs, competitive pressures, and the need for substantial additional capital, which raises significant financial uncertainties.